JDRF Invests in TetraGenetics’ Innovative Approach to Type 1 Diabetes Prevention

A unique scientific approach to preventing, treating and, perhaps one day, curing type 1 diabetes is being coupled with JDRF’s equally innovative approach to funding such studies in a new partnership that might move the promise of a preventive therapy and improved treatment for the condition closer to reality.

“This is a very targeted therapeutic approach to addressing type 1 diabetes,” says Dr. Ted Clark, the Chief Scientific Officer for TetraGenetics, a company that has been working for the past several years on developing drugs to prevent and treat diabetes. “Our technology has the potential to effectively block the specific autoimmunity response that is responsible for causing the disease.” Read more >>